Role of 18F‐FDG‐PET/CT in the management of Burkitt lymphoma. (January 2015)

• Record Type: Journal Article
• Authors: Carrillo‐Cruz, Estrella; Marín‐Oyaga, Víctor A.; Rodríguez, María Solé; Borrego‐Dorado, Isabel; de la Cruz Vicente, Fátima; Quiroga Cantero, Eduardo; Pérez, Marina Manzanares; Capote, Francisco J.; Ramírez Sánchez, María J.; Espigado Tocino, Ildefonso; Pérez‐Vega, Herminia; Vázquez‐Albertino, Ricardo; Pérez‐Simón, Jose A.
• Is Part Of: European journal of haematology. Volume 94:Number 1(2015:Jan.)
• Page Start: 23
• Page End: 30
• Publication Date: 2015-01
• Subjects: Hematology -- Periodicals; Blood -- Diseases -- Periodicals; Blood -- Periodicals; 616.15005
• DOI: 10.1111/ejh.12284
• Languages: English
• ISSNs: 0902-4441

Abstract

<abstract abstract-type="main" id="ejh12284-abs-0001"> <title>Abstract</title> <sec id="ejh12284-sec-0001" sec-type="section"> <p>Burkitt lymphoma (BL) is highly FDG‐avid even though its usefulness in the management of these patients is still controversial.</p> </sec> <sec id="ejh12284-sec-0002" sec-type="section"> <title>Aim</title> <p>We analyzed the role of positron emission tomography/computerized tomography (PET/CT) in staging newly diagnosed patients with BL and evaluating disease after first‐line chemotherapy.</p> </sec> <sec id="ejh12284-sec-0003" sec-type="section"> <title>Methods</title> <p>Fifty‐two PET/CTs were performed in 32 patients (20 at diagnosis, 27 after treatment, five to monitor residual disease). Involved areas were retrospectively compared with those observed in contrast‐enhanced CT.</p> </sec> <sec id="ejh12284-sec-0004" sec-type="section"> <title>Results</title> <p>Discrepancies were found in 64.7% of patients for whom results of both tests at diagnosis were available (<italic>n</italic> = 17), most of them involving extranodal sites. Regarding response assessment, discrepancies were observed in 38% of patients with both tests (5/13): residual masses detected by CT with negative PET/CT. Of 27 patients with post‐treatment PET/CT, 22 were in complete remission whereas one true‐positive and four false‐positive lesions (two nodal and two extranodal) were detected. With a median follow‐up of 27 months, 22 patients with negative PET/CT did not relapse. Thus, negative predictive value (NPV) was 100%. With respect to positive predictive value (PPV), one of five patients with positive assays after treatment died due to progression while the remaining four had false‐positive lesions. Nevertheless, for these four patients, mean SUVmax at nodal sites was 4.1 vs. 14.9 at diagnosis, while mean SUVmax at extranodal sites was 3.8 vs. 12.1. Thus, with a cutoff value for SUVmax <66% of that observed at diagnosis, PPV was also 100%.</p> </sec> <sec id="ejh12284-sec-0005" sec-type="section"> <title>Conclusion</title> <p>More accurate staging can be achieved using PET/CT. NPV reaches 100%, and using a ΔSUV <66%, a high PPV is also observed.</p> </sec> </abstract>